172 related articles for article (PubMed ID: 33146805)
1. The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model.
Kagabu M; Yoshino N; Saito T; Miura Y; Takeshita R; Murakami K; Kawamura H; Baba T; Sugiyama T
Int J Clin Oncol; 2021 Mar; 26(3):591-597. PubMed ID: 33146805
[TBL] [Abstract][Full Text] [Related]
2. Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.
Kagabu M; Yoshino N; Murakami K; Kawamura H; Sasaki Y; Muraki Y; Baba T
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768352
[TBL] [Abstract][Full Text] [Related]
3. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
4. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Esaki S; Goshima F; Kimura H; Murakami S; Nishiyama Y
Int J Cancer; 2013 Apr; 132(7):1592-601. PubMed ID: 22949155
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy.
Wang W; Xia X; Wang S; Sima N; Li Y; Han Z; Gao Q; Luo A; Li K; Meng L; Zhou J; Wang C; Shen K; Ma D
Cancer Gene Ther; 2011 Nov; 18(11):825-36. PubMed ID: 21852812
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
10. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.
Nakatake R; Kaibori M; Nakamura Y; Tanaka Y; Matushima H; Okumura T; Murakami T; Ino Y; Todo T; Kon M
Cancer Sci; 2018 Mar; 109(3):600-610. PubMed ID: 29288515
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.
Kato T; Nakamori M; Matsumura S; Nakamura M; Ojima T; Fukuhara H; Ino Y; Todo T; Yamaue H
Oncol Lett; 2021 Jun; 21(6):490. PubMed ID: 33968206
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
13. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.
Yu Z; Li S; Huang YY; Lin SF; Fong Y; Wong RJ
Clin Cancer Res; 2008 Mar; 14(6):1897-904. PubMed ID: 18347193
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
17. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection.
Daling JR; Madeleine MM; McKnight B; Carter JJ; Wipf GC; Ashley R; Schwartz SM; Beckmann AM; Hagensee ME; Mandelson MT; Galloway DA
Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):541-8. PubMed ID: 8827359
[TBL] [Abstract][Full Text] [Related]
18. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.
Bennett JJ; Malhotra S; Wong RJ; Delman K; Zager J; St-Louis M; Johnson P; Fong Y
Ann Surg; 2001 Jun; 233(6):819-26. PubMed ID: 11371740
[TBL] [Abstract][Full Text] [Related]
20. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
